Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Az imatinib-mezilát és a kombinált kemoterápia újonnan diagnosztizált Philadelphia kromoszóma-pozitív akut limfoblasztos leukémiában szenvedő betegek kezelésében

2026. szeptember 30. frissítette: Children's Oncology Group

Nemzetközi 3. fázisú kísérlet Philadelphia kromoszóma-pozitív akut limfoblasztos leukémiában (Ph+ALL) Az imatinib tesztelése két különböző citotoxikus kemoterápiás gerinccel kombinálva

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.

A tanulmány áttekintése

Állapot

Aktív, nem toborzó

Körülmények

Beavatkozás / kezelés

Részletes leírás

PRIMARY OBJECTIVE:

I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.

SECONDARY OBJECTIVES:

I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.

III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.

IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.

V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.

VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.

EXPLORATORY OBJECTIVES:

I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.

II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.

III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.

IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.

IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.

IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.

VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.

VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).

VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.

VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.

X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.

XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.

XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.

OUTLINE:

INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.

INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.

INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.

POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.

ARM A (SR patients assigned to ARM A):

CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.

INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.

MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.

ARM B (SR PATIENTS ASSIGNED TO ARM B):

INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.

INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.

MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.

ARM C (HR PATIENTS):

CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.

HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.

POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.

After completion of study treatment, patients are followed up every year for 3 years.

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

352

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

      • Vienna, Ausztria, 1090
        • St. Anna Children's Hospital
    • New South Wales
      • Hunter Regional Mail Centre, New South Wales, Ausztrália, 2310
        • John Hunter Children's Hospital
      • Randwick, New South Wales, Ausztrália, 2031
        • Sydney Children's Hospital
      • Westmead, New South Wales, Ausztrália, 2145
        • The Children's Hospital at Westmead
    • Queensland
      • South Brisbane, Queensland, Ausztrália, 4101
        • Queensland Children's Hospital
    • Western Australia
      • Perth, Western Australia, Ausztrália, 6008
        • Princess Margaret Hospital for Children
      • Perth, Western Australia, Ausztrália, 6009
        • Perth Children's Hospital
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgium, 3000
        • Hospitals Leuven
      • Santiago, Chile
        • Hospital Roberto del Rio-Universidad de Chile
      • Prague, Csehország, 15018, 5-Motol
        • University Hospital Motol
    • Alabama
      • Birmingham, Alabama, Egyesült Államok, 35233
        • Children's Hospital of Alabama
      • Mobile, Alabama, Egyesült Államok, 36604
        • USA Health Strada Patient Care Center
    • Alaska
      • Anchorage, Alaska, Egyesült Államok, 99508
        • Providence Alaska Medical Center
    • Arizona
      • Mesa, Arizona, Egyesült Államok, 85202
        • Banner Children's at Desert
      • Phoenix, Arizona, Egyesült Államok, 85016
        • Phoenix Childrens Hospital
      • Tucson, Arizona, Egyesült Államok, 85719
        • Banner University Medical Center - Tucson
    • Arkansas
      • Little Rock, Arkansas, Egyesült Államok, 72202-3591
        • Arkansas Children's Hospital
    • California
      • Downey, California, Egyesült Államok, 90242
        • Kaiser Permanente Downey Medical Center
      • Duarte, California, Egyesült Államok, 91010
        • City of Hope Comprehensive Cancer Center
      • Loma Linda, California, Egyesült Államok, 92354
        • Loma Linda University Medical Center
      • Long Beach, California, Egyesült Államok, 90806
        • Miller Children's and Women's Hospital Long Beach
      • Los Angeles, California, Egyesült Államok, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Egyesült Államok, 90027
        • Children's Hospital Los Angeles
      • Madera, California, Egyesült Államok, 93636
        • Valley Children's Hospital
      • Oakland, California, Egyesült Államok, 94609
        • UCSF Benioff Children's Hospital Oakland
      • Oakland, California, Egyesült Államok, 94611
        • Kaiser Permanente-Oakland
      • Orange, California, Egyesült Államok, 92868
        • Children's Hospital of Orange County
      • Palo Alto, California, Egyesült Államok, 94304
        • Lucile Packard Children's Hospital Stanford University
      • Sacramento, California, Egyesült Államok, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, Egyesült Államok, 92123
        • Rady Children's Hospital - San Diego
      • San Francisco, California, Egyesült Államok, 94158
        • UCSF Medical Center-Mission Bay
    • Colorado
      • Aurora, Colorado, Egyesült Államok, 80045
        • Children's Hospital Colorado
      • Denver, Colorado, Egyesült Államok, 80218
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
    • Connecticut
      • Hartford, Connecticut, Egyesült Államok, 06106
        • Connecticut Children's Medical Center
      • New Haven, Connecticut, Egyesült Államok, 06520
        • Yale University
    • Delaware
      • Wilmington, Delaware, Egyesült Államok, 19803
        • Alfred I duPont Hospital for Children
    • District of Columbia
      • Washington D.C., District of Columbia, Egyesült Államok, 20010
        • Children's National Medical Center
      • Washington D.C., District of Columbia, Egyesült Államok, 20007
        • MedStar Georgetown University Hospital
    • Florida
      • Fort Lauderdale, Florida, Egyesült Államok, 33316
        • Broward Health Medical Center
      • Fort Myers, Florida, Egyesült Államok, 33908
        • Golisano Children's Hospital of Southwest Florida
      • Gainesville, Florida, Egyesült Államok, 32610
        • UF Health Cancer Institute - Gainesville
      • Hollywood, Florida, Egyesült Államok, 33021
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
      • Jacksonville, Florida, Egyesült Államok, 32207
        • Nemours Children's Clinic-Jacksonville
      • Loxahatchee Groves, Florida, Egyesült Államok, 33470
        • Palms West Radiation Therapy
      • Miami, Florida, Egyesült Államok, 33155
        • Nicklaus Children's Hospital
      • Miami, Florida, Egyesült Államok, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami, Florida, Egyesült Államok, 33176
        • Miami Cancer Institute
      • Orlando, Florida, Egyesült Államok, 32827
        • Nemours Children's Hospital
      • Orlando, Florida, Egyesült Államok, 32803
        • AdventHealth Orlando
      • Orlando, Florida, Egyesült Államok, 32806
        • Arnold Palmer Hospital for Children
      • Pensacola, Florida, Egyesült Államok, 32504
        • Sacred Heart Hospital
      • St. Petersburg, Florida, Egyesült Államok, 33701
        • Johns Hopkins All Children's Hospital
      • Tampa, Florida, Egyesült Államok, 33606
        • Tampa General Hospital
      • Tampa, Florida, Egyesült Államok, 33607
        • Saint Joseph's Hospital/Children's Hospital-Tampa
      • West Palm Beach, Florida, Egyesült Államok, 33407
        • Saint Mary's Medical Center
    • Georgia
      • Atlanta, Georgia, Egyesült Államok, 30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
      • Augusta, Georgia, Egyesült Államok, 30912
        • Augusta University Medical Center
      • Macon, Georgia, Egyesült Államok, 31201
        • Atrium Health Navicent
      • Savannah, Georgia, Egyesült Államok, 31404
        • Memorial Health University Medical Center
    • Hawaii
      • Honolulu, Hawaii, Egyesült Államok, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Egyesült Államok, 83712
        • Saint Luke's Cancer Institute - Boise
    • Illinois
      • Chicago, Illinois, Egyesült Államok, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Egyesült Államok, 60612
        • University of Illinois
      • Chicago, Illinois, Egyesült Államok, 60611
        • Lurie Children's Hospital-Chicago
      • Oak Lawn, Illinois, Egyesült Államok, 60453
        • Advocate Children's Hospital-Oak Lawn
      • Park Ridge, Illinois, Egyesült Államok, 60068
        • Advocate Children's Hospital-Park Ridge
      • Peoria, Illinois, Egyesült Államok, 61637
        • OSF Children's Hospital of Illinois
      • Springfield, Illinois, Egyesült Államok, 62702
        • Southern Illinois University School of Medicine
    • Indiana
      • Indianapolis, Indiana, Egyesült Államok, 46202
        • Riley Hospital for Children
      • Indianapolis, Indiana, Egyesült Államok, 46260
        • Ascension Saint Vincent Indianapolis Hospital
    • Iowa
      • Des Moines, Iowa, Egyesült Államok, 50309
        • Blank Children's Hospital
      • Iowa City, Iowa, Egyesült Államok, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
    • Kentucky
      • Lexington, Kentucky, Egyesült Államok, 40536
        • University of Kentucky/Markey Cancer Center
      • Louisville, Kentucky, Egyesült Államok, 40202
        • Norton Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Egyesült Államok, 70121
        • Ochsner Medical Center Jefferson
    • Maine
      • Bangor, Maine, Egyesült Államok, 04401
        • Eastern Maine Medical Center
      • Scarborough, Maine, Egyesült Államok, 04074
        • Maine Children's Cancer Program
    • Maryland
      • Baltimore, Maryland, Egyesült Államok, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Egyesült Államok, 21215
        • Sinai Hospital of Baltimore
      • Bethesda, Maryland, Egyesült Államok, 20889-5600
        • Walter Reed National Military Medical Center
    • Massachusetts
      • Boston, Massachusetts, Egyesült Államok, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Egyesült Államok, 02114
        • Massachusetts General Hospital Cancer Center
      • Boston, Massachusetts, Egyesült Államok, 02111
        • Tufts Children's Hospital
      • Worcester, Massachusetts, Egyesült Államok, 01655
        • UMass Memorial Medical Center - University Campus
    • Michigan
      • Ann Arbor, Michigan, Egyesült Államok, 48109
        • C S Mott Children's Hospital
      • Detroit, Michigan, Egyesült Államok, 48201
        • Children's Hospital of Michigan
      • Detroit, Michigan, Egyesült Államok, 48236
        • Henry Ford Health Saint John Hospital
      • East Lansing, Michigan, Egyesült Államok, 48823
        • Michigan State University
      • Grand Rapids, Michigan, Egyesült Államok, 49503
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Kalamazoo, Michigan, Egyesült Államok, 49007
        • Bronson Methodist Hospital
      • Royal Oak, Michigan, Egyesült Államok, 48073
        • Corewell Health Children's
    • Minnesota
      • Minneapolis, Minnesota, Egyesült Államok, 55404
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
      • Minneapolis, Minnesota, Egyesült Államok, 55455
        • University of Minnesota/Masonic Cancer Center
    • Mississippi
      • Jackson, Mississippi, Egyesült Államok, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Columbia, Missouri, Egyesült Államok, 65212
        • University of Missouri Children's Hospital
      • Kansas City, Missouri, Egyesült Államok, 64108
        • Children's Mercy Hospitals and Clinics
      • St Louis, Missouri, Egyesült Államok, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Egyesült Államok, 63141
        • Mercy Hospital Saint Louis
    • Nebraska
      • Omaha, Nebraska, Egyesült Államok, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Egyesült Államok, 68114
        • Children's Hospital and Medical Center of Omaha
    • Nevada
      • Las Vegas, Nevada, Egyesült Államok, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, Egyesült Államok, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, Egyesült Államok, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Egyesült Államok, 89102
        • University Medical Center of Southern Nevada
      • Reno, Nevada, Egyesült Államok, 89502
        • Renown Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, Egyesült Államok, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • Hackensack, New Jersey, Egyesült Államok, 07601
        • Hackensack University Medical Center
      • Morristown, New Jersey, Egyesült Államok, 07960
        • Morristown Medical Center
      • Neptune City, New Jersey, Egyesült Államok, 07753
        • Jersey Shore Medical Center
      • New Brunswick, New Jersey, Egyesült Államok, 08901
        • Saint Peter's University Hospital
      • New Brunswick, New Jersey, Egyesült Államok, 08903
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
      • Newark, New Jersey, Egyesült Államok, 07112
        • Newark Beth Israel Medical Center
      • Paterson, New Jersey, Egyesült Államok, 07503
        • Saint Joseph's Regional Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Egyesült Államok, 87106
        • Presbyterian Hospital
      • Albuquerque, New Mexico, Egyesült Államok, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Egyesült Államok, 12208
        • Albany Medical Center
      • Brooklyn, New York, Egyesült Államok, 11219
        • Maimonides Medical Center
      • Buffalo, New York, Egyesült Államok, 14263
        • Roswell Park Cancer Institute
      • Mineola, New York, Egyesült Államok, 11501
        • NYU Langone Hospital - Long Island
      • New Hyde Park, New York, Egyesült Államok, 11040
        • The Steven and Alexandra Cohen Children's Medical Center of New York
      • New York, New York, Egyesült Államok, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Egyesült Államok, 10029
        • Mount Sinai Hospital
      • New York, New York, Egyesült Államok, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, Egyesült Államok, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester, New York, Egyesült Államok, 14642
        • University of Rochester
      • Stony Brook, New York, Egyesült Államok, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, Egyesült Államok, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, Egyesült Államok, 10467
        • Montefiore Medical Center - Moses Campus
      • Valhalla, New York, Egyesült Államok, 10595
        • New York Medical College
    • North Carolina
      • Asheville, North Carolina, Egyesült Államok, 28801
        • Mission Hospital
      • Chapel Hill, North Carolina, Egyesült Államok, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, Egyesült Államok, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Charlotte, North Carolina, Egyesült Államok, 28204
        • Novant Health Presbyterian Medical Center
      • Durham, North Carolina, Egyesült Államok, 27710
        • Duke University Medical Center
      • Greenville, North Carolina, Egyesült Államok, 27834
        • East Carolina University
      • Winston-Salem, North Carolina, Egyesült Államok, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Fargo, North Dakota, Egyesült Államok, 58122
        • Sanford Broadway Medical Center
    • Ohio
      • Akron, Ohio, Egyesült Államok, 44308
        • Children's Hospital Medical Center of Akron
      • Cincinnati, Ohio, Egyesült Államok, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Egyesült Államok, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Egyesült Államok, 44106
        • Rainbow Babies and Childrens Hospital
      • Columbus, Ohio, Egyesült Államok, 43205
        • Nationwide Children's Hospital
      • Dayton, Ohio, Egyesült Államok, 45404
        • Dayton Children's Hospital
      • Toledo, Ohio, Egyesült Államok, 43606
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Egyesült Államok, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, Egyesült Államok, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Egyesült Államok, 97227
        • Legacy Emanuel Children's Hospital
    • Pennsylvania
      • Allentown, Pennsylvania, Egyesült Államok, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Danville, Pennsylvania, Egyesült Államok, 17822
        • Geisinger Medical Center
      • Hershey, Pennsylvania, Egyesült Államok, 17033
        • Penn State Children's Hospital
      • Philadelphia, Pennsylvania, Egyesült Államok, 19104
        • Children's Hospital of Philadelphia
      • Philadelphia, Pennsylvania, Egyesült Államok, 19134
        • Saint Christopher's Hospital for Children
      • Pittsburgh, Pennsylvania, Egyesült Államok, 15224
        • Children's Hospital of Pittsburgh of UPMC
    • Rhode Island
      • Providence, Rhode Island, Egyesült Államok, 02903
        • Rhode Island Hospital
    • South Carolina
      • Charleston, South Carolina, Egyesült Államok, 29425
        • Medical University of South Carolina
      • Columbia, South Carolina, Egyesült Államok, 29203
        • Prisma Health Richland Hospital
      • Greenville, South Carolina, Egyesült Államok, 29605
        • BI-LO Charities Children's Cancer Center
    • South Dakota
      • Sioux Falls, South Dakota, Egyesült Államok, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Chattanooga, Tennessee, Egyesült Államok, 37403
        • T C Thompson Children's Hospital
      • Knoxville, Tennessee, Egyesült Államok, 37916
        • East Tennessee Childrens Hospital
      • Nashville, Tennessee, Egyesült Államok, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Egyesült Államok, 37203
        • The Children's Hospital at TriStar Centennial
    • Texas
      • Amarillo, Texas, Egyesült Államok, 79106
        • Texas Tech University Health Sciences Center-Amarillo
      • Austin, Texas, Egyesült Államok, 78723
        • Dell Children's Medical Center of Central Texas
      • Corpus Christi, Texas, Egyesült Államok, 78411
        • Driscoll Children's Hospital
      • Dallas, Texas, Egyesült Államok, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Dallas, Texas, Egyesült Államok, 75230
        • Medical City Dallas Hospital
      • El Paso, Texas, Egyesült Államok, 79905
        • El Paso Children's Hospital
      • Fort Worth, Texas, Egyesült Államok, 76104
        • Cook Children's Medical Center
      • Houston, Texas, Egyesült Államok, 77030
        • UT MD Anderson Cancer Center
      • Houston, Texas, Egyesült Államok, 77030
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
      • Lubbock, Texas, Egyesült Államok, 79410
        • Covenant Children's Hospital
      • Lubbock, Texas, Egyesült Államok, 79415
        • UMC Cancer Center / UMC Health System
      • San Antonio, Texas, Egyesült Államok, 78207
        • Children's Hospital of San Antonio
      • San Antonio, Texas, Egyesült Államok, 78229
        • Methodist Children's Hospital of South Texas
      • Temple, Texas, Egyesült Államok, 76508
        • Scott and White Memorial Hospital
    • Utah
      • Salt Lake City, Utah, Egyesült Államok, 84113
        • Primary Children's Hospital
    • Vermont
      • Burlington, Vermont, Egyesült Államok, 05405
        • University of Vermont and State Agricultural College
    • Virginia
      • Charlottesville, Virginia, Egyesült Államok, 22908
        • University of Virginia Cancer Center
      • Falls Church, Virginia, Egyesült Államok, 22042
        • Inova Fairfax Hospital
      • Norfolk, Virginia, Egyesült Államok, 23507
        • Children's Hospital of The King's Daughters
      • Portsmouth, Virginia, Egyesült Államok, 23708-2197
        • Naval Medical Center - Portsmouth
      • Richmond, Virginia, Egyesült Államok, 23298
        • VCU Massey Comprehensive Cancer Center
      • Roanoke, Virginia, Egyesült Államok, 24014
        • Carilion Children's
    • Washington
      • Seattle, Washington, Egyesült Államok, 98105
        • Seattle Children's Hospital
      • Spokane, Washington, Egyesült Államok, 99204
        • Providence Sacred Heart Medical Center and Children's Hospital
      • Tacoma, Washington, Egyesült Államok, 98405
        • Mary Bridge Children's Hospital and Health Center
      • Tacoma, Washington, Egyesült Államok, 98431
        • Madigan Army Medical Center
    • West Virginia
      • Huntington, West Virginia, Egyesült Államok, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, Egyesült Államok, 26506
        • West Virginia University Healthcare
    • Wisconsin
      • Green Bay, Wisconsin, Egyesült Államok, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Madison, Wisconsin, Egyesült Államok, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Marshfield, Wisconsin, Egyesült Államok, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Egyesült Államok, 53226
        • Children's Hospital of Wisconsin
      • Tampere, Finnország, 33521
        • Tampere University Hospital
      • Rennes, Franciaország, 35203
        • CHU Hopital Sud
      • Utrecht, Hollandia, 3584 CT
        • Princess Máxima Center for Pediatric Oncology
    • Kowloon
      • Kowloon Bay, Kowloon, Hong Kong
        • Hong Kong Children's Hospital
    • Central District
      • Petah Tikva, Central District, Izrael, 4920235
        • Schneider Children's Medical Center of Israel
      • Québec, Kanada, G1V 4G2
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
    • Alberta
      • Calgary, Alberta, Kanada, T3B 6A8
        • Alberta Children's Hospital
      • Edmonton, Alberta, Kanada, T6G 2B7
        • University of Alberta Hospital
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • British Columbia Children's Hospital
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3E 0V9
        • CancerCare Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3K 6R8
        • IWK Health Centre
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster Children's Hospital at Hamilton Health Sciences
      • Kingston, Ontario, Kanada, K7L 2V7
        • Kingston Health Sciences Centre
      • London, Ontario, Kanada, N6A 5W9
        • Children's Hospital
      • Ottawa, Ontario, Kanada, K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • Hospital for Sick Children
    • Quebec
      • Montreal, Quebec, Kanada, H3H 1P3
        • The Montreal Children's Hospital of the MUHC
      • Montreal, Quebec, Kanada, H3T 1C5
        • Centre Hospitalier Universitaire Sainte-Justine
      • Sherbrooke, Quebec, Kanada, J1H 5N4
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
    • Saskatchewan
      • Saskatoon, Saskatchewan, Kanada, S7N 4H4
        • Saskatoon Cancer Centre
      • Saskatoon, Saskatchewan, Kanada, S7N 0W8
        • Jim Pattison Children's Hospital
      • Hamburg, Németország, 20246
        • Universitätsklinik Eppendorf
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Németország, 24105
        • University Medical Center chleswig- Campus Kiel
      • Monza, Olaszország, 20900
        • Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM
      • Caguas, Puerto Rico, 00726
        • HIMA San Pablo Oncologic Hospital
      • San Juan, Puerto Rico, 00926
        • University Pediatric Hospital
      • San Juan, Puerto Rico, 00912
        • San Jorge Children's Hospital
      • Zurich, Svájc, CH8032
        • University Children's Hospital
    • Skåne County
      • Lund, Skåne County, Svédország, 22185
        • Skane University Hospital
      • Riyadh, Szaud-Arábia, 11211
        • King Faisal Specialist Hospital and Research Centre
      • Christchurch, Új Zéland, 8011
        • Christchurch Hospital
    • Auckland
      • Grafton, Auckland, Új Zéland, 1145
        • Starship Children's Hospital

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

1 év (Gyermek, Felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled

    • For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
    • In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
  • >= 1 year (365 days) and =< 21 years at ALL diagnosis

  • Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies

  • ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)

  • Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy

  • Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine

  • Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib

  • ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)

  • ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose

  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2

  • Direct bilirubin =< 2.0 mg/dL

  • Shortening fraction of >= 27% by echocardiogram

  • Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram

  • Corrected QT interval, QTc < 480 msec

    • Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:

    • 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
    • 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
    • 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
    • 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
    • 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
    • >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)

Exclusion Criteria:

  • Known history of chronic myelogenous leukemia (CML)

  • ALL developing after a previous cancer treated with cytotoxic chemotherapy

  • Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation

  • Down syndrome

  • Pregnancy and breast feeding

    • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
    • Lactating females who plan to breastfeed their infants
    • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
  • Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block

  • Prior treatment with dasatinib, or any TKI other than imatinib

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Arm A (imatinib mesylate, EsPhALL chemotherapy)

See Detailed Description

Correlative studies

Given IV

Más nevek:
  • Cytoxan
  • CTX
  • (-)-Ciklofoszfamid
  • 2H-1,3,2-oxazafoszforin, 2-[bisz(2-klór-etil)-amino]-tetrahidro-, 2-oxid, monohidrát
  • Carloxan
  • Ciklofoszfamid
  • Cikloxál
  • Clafen
  • Claphene
  • CP monohidrát
  • CYCLO-cella
  • Cikloblasztin
  • Ciklofoszfam
  • Ciklofoszfamid-monohidrát
  • Cyclophosphamidum
  • Ciklofoszfán
  • Ciklostin
  • Ciklosztin
  • Citofoszfán
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofoszfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B 518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Más nevek:
  • Adriablasztin
  • Hidroxydaunomicin
  • Hidroxil-daunorubicin
  • Hidroxildaunorubicin

Given IV

Más nevek:
  • Oncovin
  • Kyocristine
  • Leurokrisztin-szulfát
  • Leurokrisztin, szulfát
  • Vincasar
  • Vincosid
  • Vincrex
  • Vinkrisztin, szulfát

Ancillary studies

Given IV

Más nevek:
  • Cerubidin
  • Cerubidine
  • Cloridrato de Daunorubicina
  • Daunoblasztin
  • Daunoblastina
  • Daunomicin-hidroklorid
  • Daunomicin, hidroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomicin-hidroklorid
  • Rubilem

Given IV

Más nevek:
  • Demetil-epipodofillotoxin Etilidin-glükozid
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Given PO

Más nevek:
  • 6 MP
  • Purinethol
  • 3H-purin-6-tiol
  • 6 Tiohipoxantin
  • 6 Tiopurin
  • 6-Merkaptopurin
  • 6-merkaptopurin-monohidrát
  • 6-Purinetiol
  • 6-Tiopurin
  • 6-Tioxopurin
  • 6H-purin-6-tion, 1,7-dihidro-(9CI)
  • 7-merkapto-1,3,4,6-tetrazaindén
  • Alti-Merkaptopurin
  • Azathiopurin
  • Bw 57-323H
  • Flocofil
  • Ismipur
  • Leukerin
  • Leupurin
  • Mercaleukim
  • Mercaleukin
  • Mercaptina
  • Mercaptopurinum
  • Mercapurin
  • Mern
  • NCI-C04886
  • Puri-Nethol
  • Purimethol
  • Purin, 6-merkapto-
  • Purin-6-tiol (8CI)
  • Purin-6-tiol, monohidrát
  • Purinetiol
  • U-4748
  • WR-2785

Given IV

Más nevek:
  • Medrol
  • Wyacort
  • Adlone
  • Caberdelta M
  • DepMedalone
  • Depo Moderin
  • Depo-Nisolone
  • Duralone
  • Emmetipi
  • Esameton
  • Firmacort
  • Medlone 21
  • Medrát
  • Medrol Veriderm
  • Medrone
  • Mega-Star
  • Meprolon
  • Metilprednizolon
  • Metilbetazon Oldható
  • Metrocort
  • Metipresol
  • Metysolon
  • Predni-M-Tablinen
  • Prednilen
  • Radilem
  • Sieropresol
  • Solpredone
  • Summicort
  • Urbason
  • Veriderm Medrol

Given IV

Más nevek:
  • Asta Z 4942
  • Asta Z-4942
  • Cyfos
  • Holoxan
  • Holoxán
  • Ifex
  • IFO
  • IFO-Cell
  • Ifolem
  • Ifomida
  • Ifomide
  • Ifoszfamidum
  • Ifoxan
  • IFX
  • Ifoszfamid
  • Iso-Endoxan
  • Isoendoxan
  • Izofoszfamid
  • Mitoxana
  • MJF 9325
  • MJF-9325
  • Naxamid
  • Seromida
  • Tronoxal
  • Z 4942
  • Z-4942

Given IV

Más nevek:
  • Aszparagináz (Escherichia coli izoenzim II), konjugátum alfa-(((2,5-dioxo-1-pirrolidinil)oxi)karbonil)-omega-metoxipoli(oxi-1,2-etándiil)
  • Asparlas
  • EZN-2285
  • SC-PEG E. coli L-aszparagináz
  • Szukcinimidil-karbonát-monometoxi-polietilén-glikol E. coli L-aszparagináz
  • Calaspargase Pegol-mknl

Given PO or IV

Más nevek:
  • Wellcovorin
  • folinsav
  • Adinepar
  • Calcifolin
  • Kalcium (6S)-Folinát
  • Kalcium-folinát
  • Kalcium Leukovorin
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • Citrovorum faktor
  • Cromatonbic Folinico
  • Dalisol
  • Disintox
  • Divical
  • Ecofol
  • Emovis
  • Faktor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-sejt
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Folinát kalcium
  • Folinsav kalcium-só-pentahidrát
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leucosar
  • leukovorin
  • Rescufolin
  • Rescuvolin
  • Tonofolin

Given IT

Más nevek:
  • Abitrexát
  • Folex
  • Mexát
  • MTX
  • Alfa-Metopterin
  • Ametopterin
  • Brimexát
  • CL 14377
  • CL-14377
  • Emtexate
  • Emthexat
  • Emthexate
  • Farmitrexat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertrexát
  • Lumexon
  • Maxtrex
  • Medsatrexát
  • Metex
  • Metoblasztin
  • Metotrexát LPF
  • Metotrexát Metilaminopterin
  • Metotrexatum
  • Metotrexato
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Rheumatrex
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Given IV, SC, or IT

Más nevek:
  • Béta-citozin-arabinozid
  • 1-p-D-arabinofuranozil-4-amino-2(1H)pirimidinon
  • 1-béta-D-arabinofuranozilcitozin
  • 1-béta-D-arabinofuranozil-4-amino-2(1H)pirimidinon
  • 1p-D-arabinofuranozilcitozin
  • 2(1H)-pirimidinon, 4-amino-1-béta-D-arabinofuranozil-
  • 2(1H)-pirimidinon, 4-amino-1 p-D-arabinofuranozil-
  • Alexan
  • Ara-C
  • ARA-cella
  • Arab
  • Arabinofuranozilcitozin
  • Arabinozilcitozin
  • Aracitidin
  • Aracitin
  • Béta-citozin arabinosid
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Citozin arabinosid
  • Citozin-béta-arabinozid
  • Erpalfa
  • Starasid
  • Tarabine PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given PO or IV

Más nevek:
  • Decadron
  • Hemady
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron DP
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorén
  • Deronil
  • Dezametazon
  • Desameton
  • Dexa-Mamalet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorén
  • Dexalocal
  • Dexamecortin
  • Dexamet
  • Dexametazon Intensol
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Dxevo
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Metilfluorprednizolon
  • Millicorten
  • Mymetazon
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazon
  • ZoDex
  • LenaDex

Given IV

Más nevek:
  • Cardioxane
  • Totect
  • Zinecard

Given SC or IV

Más nevek:
  • G-CSF
  • r-metHuG-CSF
  • Neupogen
  • Filgrastim-aafi
  • Nivestym
  • Rekombináns metionil humán granulocita kolónia stimuláló faktor
  • rG-CSF
  • Tevagrastim
  • Filgrastim Biohasonló Filgrastim-sndz
  • Zarxio
  • Filgrastim XM02
  • Tbo-filgrasztim
  • Granix
  • Nivestim
  • XM02
  • Filgrastim-sndz
  • Filgrastim Biohasonló Tbo-filgrasztim
  • Filgrastim-ayow
  • Releuko
  • Semleges

Given PO

Más nevek:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
  • CGP-57148B
  • CGP 57148B
  • CGP-57148
  • CGP57148
  • Imarech
  • Imat
  • Imkeldi

Given PO or IV

Más nevek:
  • Levofolinsav
  • Levofolinát
  • CL-307,782
  • Elvorine, izovorin, levofolén, levorin
  • Izovorin
  • L-leukovorin
  • Khapzory

Given IV

Más nevek:
  • L-aszparagináz polietilénglikollal
  • Oncaspar
  • Oncaspar-IV
  • PEG-aszparagináz
  • PEG-L-aszparagináz
  • PEG-L-aszparagináz (Enzon – Kyowa Hakko)
  • PEGLA
  • Polietilén-glikol-L-aszparagináz

Given PO

Más nevek:
  • (11béta)-11,17,21-trihidroxi-pregna-1,4-dién-3,20-dion
  • .delta.1-Hidrokortizon
  • Adnizolon
  • Aprednislon
  • Kapszoid
  • Cortalone
  • Kortizolon
  • Dacortin H
  • Dekaprednil
  • Decortin H
  • Delta (1) Hidrokortizon
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-Phoricol
  • Delta1-dehidro-hidrokortizon
  • Deltacortril
  • Deltahidrokortizon
  • Deltasolone
  • Deltidrosol
  • Dhasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolone
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralon
  • Meti Derm
  • Metikortelon
  • Opredsone
  • Panafcortelone
  • Prekortizil
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolonum
  • Prelone
  • Prenilon
  • Sterane

Given IT

Más nevek:
  • Aeroseb-HC
  • Barseb HC
  • Barseb-HC
  • Cetacort
  • Cort-Dome
  • Cortef
  • Cortenema
  • Cortifan
  • Kortizol
  • Cortispray
  • Cortril
  • Dermacort
  • Domolene
  • Eldecort
  • Hautosone
  • Heb-Cort
  • Hidrokortizon
  • Hidrokorton
  • Hytone
  • Komed-HC
  • Nutracort
  • Proctocort
  • Rectoid

Given PO

Más nevek:
  • 6-TG
  • 2-amino 6 MP
  • 2-amino-1,7-dihidro-6H-purin-6-tion
  • 2-amino-6-merkaptopurin
  • 2-amino-6-purin-tiol
  • 2-aminopurin-6-tiol
  • 2-aminopurin-6(1H)-tion
  • 2-aminopurin-6-tiol-hemihidrát
  • 2-merkapto-6-aminopurin
  • 6-amino-2-merkaptopurin
  • 6-merkapto-2-aminopurin
  • 6-merkaptoguanin
  • 6H-purin-6-tion, 2-amino-1,7-dihidro-(9CI)
  • BW 5071
  • Lanvis
  • Bulvárlap
  • Tioguanin-hemihidrát
  • Tioguanin-hidrát
  • Tioguanin
  • Tioguanine
  • Üdv, U3B
  • WR-1141
  • X 27
Kísérleti: Arm B (imatinib mesylate, COG/BFM chemotherapy)

See Detailed Description.

Correlative studies

Given IV

Más nevek:
  • Cytoxan
  • CTX
  • (-)-Ciklofoszfamid
  • 2H-1,3,2-oxazafoszforin, 2-[bisz(2-klór-etil)-amino]-tetrahidro-, 2-oxid, monohidrát
  • Carloxan
  • Ciklofoszfamid
  • Cikloxál
  • Clafen
  • Claphene
  • CP monohidrát
  • CYCLO-cella
  • Cikloblasztin
  • Ciklofoszfam
  • Ciklofoszfamid-monohidrát
  • Cyclophosphamidum
  • Ciklofoszfán
  • Ciklostin
  • Ciklosztin
  • Citofoszfán
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofoszfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B 518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Más nevek:
  • Adriablasztin
  • Hidroxydaunomicin
  • Hidroxil-daunorubicin
  • Hidroxildaunorubicin

Given IV

Más nevek:
  • Oncovin
  • Kyocristine
  • Leurokrisztin-szulfát
  • Leurokrisztin, szulfát
  • Vincasar
  • Vincosid
  • Vincrex
  • Vinkrisztin, szulfát

Ancillary studies

Given PO

Más nevek:
  • 6 MP
  • Purinethol
  • 3H-purin-6-tiol
  • 6 Tiohipoxantin
  • 6 Tiopurin
  • 6-Merkaptopurin
  • 6-merkaptopurin-monohidrát
  • 6-Purinetiol
  • 6-Tiopurin
  • 6-Tioxopurin
  • 6H-purin-6-tion, 1,7-dihidro-(9CI)
  • 7-merkapto-1,3,4,6-tetrazaindén
  • Alti-Merkaptopurin
  • Azathiopurin
  • Bw 57-323H
  • Flocofil
  • Ismipur
  • Leukerin
  • Leupurin
  • Mercaleukim
  • Mercaleukin
  • Mercaptina
  • Mercaptopurinum
  • Mercapurin
  • Mern
  • NCI-C04886
  • Puri-Nethol
  • Purimethol
  • Purin, 6-merkapto-
  • Purin-6-tiol (8CI)
  • Purin-6-tiol, monohidrát
  • Purinetiol
  • U-4748
  • WR-2785

Given IV

Más nevek:
  • Medrol
  • Wyacort
  • Adlone
  • Caberdelta M
  • DepMedalone
  • Depo Moderin
  • Depo-Nisolone
  • Duralone
  • Emmetipi
  • Esameton
  • Firmacort
  • Medlone 21
  • Medrát
  • Medrol Veriderm
  • Medrone
  • Mega-Star
  • Meprolon
  • Metilprednizolon
  • Metilbetazon Oldható
  • Metrocort
  • Metipresol
  • Metysolon
  • Predni-M-Tablinen
  • Prednilen
  • Radilem
  • Sieropresol
  • Solpredone
  • Summicort
  • Urbason
  • Veriderm Medrol

Given IV

Más nevek:
  • Aszparagináz (Escherichia coli izoenzim II), konjugátum alfa-(((2,5-dioxo-1-pirrolidinil)oxi)karbonil)-omega-metoxipoli(oxi-1,2-etándiil)
  • Asparlas
  • EZN-2285
  • SC-PEG E. coli L-aszparagináz
  • Szukcinimidil-karbonát-monometoxi-polietilén-glikol E. coli L-aszparagináz
  • Calaspargase Pegol-mknl

Given PO or IV

Más nevek:
  • Wellcovorin
  • folinsav
  • Adinepar
  • Calcifolin
  • Kalcium (6S)-Folinát
  • Kalcium-folinát
  • Kalcium Leukovorin
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • Citrovorum faktor
  • Cromatonbic Folinico
  • Dalisol
  • Disintox
  • Divical
  • Ecofol
  • Emovis
  • Faktor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-sejt
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Folinát kalcium
  • Folinsav kalcium-só-pentahidrát
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leucosar
  • leukovorin
  • Rescufolin
  • Rescuvolin
  • Tonofolin

Given IT

Más nevek:
  • Abitrexát
  • Folex
  • Mexát
  • MTX
  • Alfa-Metopterin
  • Ametopterin
  • Brimexát
  • CL 14377
  • CL-14377
  • Emtexate
  • Emthexat
  • Emthexate
  • Farmitrexat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertrexát
  • Lumexon
  • Maxtrex
  • Medsatrexát
  • Metex
  • Metoblasztin
  • Metotrexát LPF
  • Metotrexát Metilaminopterin
  • Metotrexatum
  • Metotrexato
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Rheumatrex
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Given IV, SC, or IT

Más nevek:
  • Béta-citozin-arabinozid
  • 1-p-D-arabinofuranozil-4-amino-2(1H)pirimidinon
  • 1-béta-D-arabinofuranozilcitozin
  • 1-béta-D-arabinofuranozil-4-amino-2(1H)pirimidinon
  • 1p-D-arabinofuranozilcitozin
  • 2(1H)-pirimidinon, 4-amino-1-béta-D-arabinofuranozil-
  • 2(1H)-pirimidinon, 4-amino-1 p-D-arabinofuranozil-
  • Alexan
  • Ara-C
  • ARA-cella
  • Arab
  • Arabinofuranozilcitozin
  • Arabinozilcitozin
  • Aracitidin
  • Aracitin
  • Béta-citozin arabinosid
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Citozin arabinosid
  • Citozin-béta-arabinozid
  • Erpalfa
  • Starasid
  • Tarabine PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given PO or IV

Más nevek:
  • Decadron
  • Hemady
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron DP
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorén
  • Deronil
  • Dezametazon
  • Desameton
  • Dexa-Mamalet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorén
  • Dexalocal
  • Dexamecortin
  • Dexamet
  • Dexametazon Intensol
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Dxevo
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Metilfluorprednizolon
  • Millicorten
  • Mymetazon
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazon
  • ZoDex
  • LenaDex

Given IV

Más nevek:
  • Cardioxane
  • Totect
  • Zinecard

Given PO

Más nevek:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
  • CGP-57148B
  • CGP 57148B
  • CGP-57148
  • CGP57148
  • Imarech
  • Imat
  • Imkeldi

Given PO or IV

Más nevek:
  • Levofolinsav
  • Levofolinát
  • CL-307,782
  • Elvorine, izovorin, levofolén, levorin
  • Izovorin
  • L-leukovorin
  • Khapzory

Given IV

Más nevek:
  • L-aszparagináz polietilénglikollal
  • Oncaspar
  • Oncaspar-IV
  • PEG-aszparagináz
  • PEG-L-aszparagináz
  • PEG-L-aszparagináz (Enzon – Kyowa Hakko)
  • PEGLA
  • Polietilén-glikol-L-aszparagináz

Given PO

Más nevek:
  • (11béta)-11,17,21-trihidroxi-pregna-1,4-dién-3,20-dion
  • .delta.1-Hidrokortizon
  • Adnizolon
  • Aprednislon
  • Kapszoid
  • Cortalone
  • Kortizolon
  • Dacortin H
  • Dekaprednil
  • Decortin H
  • Delta (1) Hidrokortizon
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-Phoricol
  • Delta1-dehidro-hidrokortizon
  • Deltacortril
  • Deltahidrokortizon
  • Deltasolone
  • Deltidrosol
  • Dhasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolone
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralon
  • Meti Derm
  • Metikortelon
  • Opredsone
  • Panafcortelone
  • Prekortizil
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolonum
  • Prelone
  • Prenilon
  • Sterane

Given PO

Más nevek:
  • 6-TG
  • 2-amino 6 MP
  • 2-amino-1,7-dihidro-6H-purin-6-tion
  • 2-amino-6-merkaptopurin
  • 2-amino-6-purin-tiol
  • 2-aminopurin-6-tiol
  • 2-aminopurin-6(1H)-tion
  • 2-aminopurin-6-tiol-hemihidrát
  • 2-merkapto-6-aminopurin
  • 6-amino-2-merkaptopurin
  • 6-merkapto-2-aminopurin
  • 6-merkaptoguanin
  • 6H-purin-6-tion, 2-amino-1,7-dihidro-(9CI)
  • BW 5071
  • Lanvis
  • Bulvárlap
  • Tioguanin-hemihidrát
  • Tioguanin-hidrát
  • Tioguanin
  • Tioguanine
  • Üdv, U3B
  • WR-1141
  • X 27
Kísérleti: Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)

See Detailed Description

Correlative studies

Given IV

Más nevek:
  • Cytoxan
  • CTX
  • (-)-Ciklofoszfamid
  • 2H-1,3,2-oxazafoszforin, 2-[bisz(2-klór-etil)-amino]-tetrahidro-, 2-oxid, monohidrát
  • Carloxan
  • Ciklofoszfamid
  • Cikloxál
  • Clafen
  • Claphene
  • CP monohidrát
  • CYCLO-cella
  • Cikloblasztin
  • Ciklofoszfam
  • Ciklofoszfamid-monohidrát
  • Cyclophosphamidum
  • Ciklofoszfán
  • Ciklostin
  • Ciklosztin
  • Citofoszfán
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofoszfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B 518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Más nevek:
  • Adriablasztin
  • Hidroxydaunomicin
  • Hidroxil-daunorubicin
  • Hidroxildaunorubicin

Given IV

Más nevek:
  • Oncovin
  • Kyocristine
  • Leurokrisztin-szulfát
  • Leurokrisztin, szulfát
  • Vincasar
  • Vincosid
  • Vincrex
  • Vinkrisztin, szulfát

Ancillary studies

Given IV

Más nevek:
  • Cerubidin
  • Cerubidine
  • Cloridrato de Daunorubicina
  • Daunoblasztin
  • Daunoblastina
  • Daunomicin-hidroklorid
  • Daunomicin, hidroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomicin-hidroklorid
  • Rubilem

Given IV

Más nevek:
  • Demetil-epipodofillotoxin Etilidin-glükozid
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Given PO

Más nevek:
  • 6 MP
  • Purinethol
  • 3H-purin-6-tiol
  • 6 Tiohipoxantin
  • 6 Tiopurin
  • 6-Merkaptopurin
  • 6-merkaptopurin-monohidrát
  • 6-Purinetiol
  • 6-Tiopurin
  • 6-Tioxopurin
  • 6H-purin-6-tion, 1,7-dihidro-(9CI)
  • 7-merkapto-1,3,4,6-tetrazaindén
  • Alti-Merkaptopurin
  • Azathiopurin
  • Bw 57-323H
  • Flocofil
  • Ismipur
  • Leukerin
  • Leupurin
  • Mercaleukim
  • Mercaleukin
  • Mercaptina
  • Mercaptopurinum
  • Mercapurin
  • Mern
  • NCI-C04886
  • Puri-Nethol
  • Purimethol
  • Purin, 6-merkapto-
  • Purin-6-tiol (8CI)
  • Purin-6-tiol, monohidrát
  • Purinetiol
  • U-4748
  • WR-2785

Given IV

Más nevek:
  • Medrol
  • Wyacort
  • Adlone
  • Caberdelta M
  • DepMedalone
  • Depo Moderin
  • Depo-Nisolone
  • Duralone
  • Emmetipi
  • Esameton
  • Firmacort
  • Medlone 21
  • Medrát
  • Medrol Veriderm
  • Medrone
  • Mega-Star
  • Meprolon
  • Metilprednizolon
  • Metilbetazon Oldható
  • Metrocort
  • Metipresol
  • Metysolon
  • Predni-M-Tablinen
  • Prednilen
  • Radilem
  • Sieropresol
  • Solpredone
  • Summicort
  • Urbason
  • Veriderm Medrol

Given IV

Más nevek:
  • Asta Z 4942
  • Asta Z-4942
  • Cyfos
  • Holoxan
  • Holoxán
  • Ifex
  • IFO
  • IFO-Cell
  • Ifolem
  • Ifomida
  • Ifomide
  • Ifoszfamidum
  • Ifoxan
  • IFX
  • Ifoszfamid
  • Iso-Endoxan
  • Isoendoxan
  • Izofoszfamid
  • Mitoxana
  • MJF 9325
  • MJF-9325
  • Naxamid
  • Seromida
  • Tronoxal
  • Z 4942
  • Z-4942

Given IV

Más nevek:
  • Aszparagináz (Escherichia coli izoenzim II), konjugátum alfa-(((2,5-dioxo-1-pirrolidinil)oxi)karbonil)-omega-metoxipoli(oxi-1,2-etándiil)
  • Asparlas
  • EZN-2285
  • SC-PEG E. coli L-aszparagináz
  • Szukcinimidil-karbonát-monometoxi-polietilén-glikol E. coli L-aszparagináz
  • Calaspargase Pegol-mknl

Given PO or IV

Más nevek:
  • Wellcovorin
  • folinsav
  • Adinepar
  • Calcifolin
  • Kalcium (6S)-Folinát
  • Kalcium-folinát
  • Kalcium Leukovorin
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • Citrovorum faktor
  • Cromatonbic Folinico
  • Dalisol
  • Disintox
  • Divical
  • Ecofol
  • Emovis
  • Faktor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-sejt
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Folinát kalcium
  • Folinsav kalcium-só-pentahidrát
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leucosar
  • leukovorin
  • Rescufolin
  • Rescuvolin
  • Tonofolin

Given IT

Más nevek:
  • Abitrexát
  • Folex
  • Mexát
  • MTX
  • Alfa-Metopterin
  • Ametopterin
  • Brimexát
  • CL 14377
  • CL-14377
  • Emtexate
  • Emthexat
  • Emthexate
  • Farmitrexat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertrexát
  • Lumexon
  • Maxtrex
  • Medsatrexát
  • Metex
  • Metoblasztin
  • Metotrexát LPF
  • Metotrexát Metilaminopterin
  • Metotrexatum
  • Metotrexato
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Rheumatrex
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Given IV, SC, or IT

Más nevek:
  • Béta-citozin-arabinozid
  • 1-p-D-arabinofuranozil-4-amino-2(1H)pirimidinon
  • 1-béta-D-arabinofuranozilcitozin
  • 1-béta-D-arabinofuranozil-4-amino-2(1H)pirimidinon
  • 1p-D-arabinofuranozilcitozin
  • 2(1H)-pirimidinon, 4-amino-1-béta-D-arabinofuranozil-
  • 2(1H)-pirimidinon, 4-amino-1 p-D-arabinofuranozil-
  • Alexan
  • Ara-C
  • ARA-cella
  • Arab
  • Arabinofuranozilcitozin
  • Arabinozilcitozin
  • Aracitidin
  • Aracitin
  • Béta-citozin arabinosid
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Citozin arabinosid
  • Citozin-béta-arabinozid
  • Erpalfa
  • Starasid
  • Tarabine PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given PO or IV

Más nevek:
  • Decadron
  • Hemady
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron DP
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorén
  • Deronil
  • Dezametazon
  • Desameton
  • Dexa-Mamalet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorén
  • Dexalocal
  • Dexamecortin
  • Dexamet
  • Dexametazon Intensol
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Dxevo
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Metilfluorprednizolon
  • Millicorten
  • Mymetazon
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazon
  • ZoDex
  • LenaDex

Given IV

Más nevek:
  • Cardioxane
  • Totect
  • Zinecard

Given SC or IV

Más nevek:
  • G-CSF
  • r-metHuG-CSF
  • Neupogen
  • Filgrastim-aafi
  • Nivestym
  • Rekombináns metionil humán granulocita kolónia stimuláló faktor
  • rG-CSF
  • Tevagrastim
  • Filgrastim Biohasonló Filgrastim-sndz
  • Zarxio
  • Filgrastim XM02
  • Tbo-filgrasztim
  • Granix
  • Nivestim
  • XM02
  • Filgrastim-sndz
  • Filgrastim Biohasonló Tbo-filgrasztim
  • Filgrastim-ayow
  • Releuko
  • Semleges

Given PO

Más nevek:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
  • CGP-57148B
  • CGP 57148B
  • CGP-57148
  • CGP57148
  • Imarech
  • Imat
  • Imkeldi

Given PO or IV

Más nevek:
  • Levofolinsav
  • Levofolinát
  • CL-307,782
  • Elvorine, izovorin, levofolén, levorin
  • Izovorin
  • L-leukovorin
  • Khapzory

Given IV

Más nevek:
  • L-aszparagináz polietilénglikollal
  • Oncaspar
  • Oncaspar-IV
  • PEG-aszparagináz
  • PEG-L-aszparagináz
  • PEG-L-aszparagináz (Enzon – Kyowa Hakko)
  • PEGLA
  • Polietilén-glikol-L-aszparagináz

Given PO

Más nevek:
  • (11béta)-11,17,21-trihidroxi-pregna-1,4-dién-3,20-dion
  • .delta.1-Hidrokortizon
  • Adnizolon
  • Aprednislon
  • Kapszoid
  • Cortalone
  • Kortizolon
  • Dacortin H
  • Dekaprednil
  • Decortin H
  • Delta (1) Hidrokortizon
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-Phoricol
  • Delta1-dehidro-hidrokortizon
  • Deltacortril
  • Deltahidrokortizon
  • Deltasolone
  • Deltidrosol
  • Dhasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolone
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralon
  • Meti Derm
  • Metikortelon
  • Opredsone
  • Panafcortelone
  • Prekortizil
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolonum
  • Prelone
  • Prenilon
  • Sterane

Given IT

Más nevek:
  • Aeroseb-HC
  • Barseb HC
  • Barseb-HC
  • Cetacort
  • Cort-Dome
  • Cortef
  • Cortenema
  • Cortifan
  • Kortizol
  • Cortispray
  • Cortril
  • Dermacort
  • Domolene
  • Eldecort
  • Hautosone
  • Heb-Cort
  • Hidrokortizon
  • Hidrokorton
  • Hytone
  • Komed-HC
  • Nutracort
  • Proctocort
  • Rectoid

Given PO

Más nevek:
  • 6-TG
  • 2-amino 6 MP
  • 2-amino-1,7-dihidro-6H-purin-6-tion
  • 2-amino-6-merkaptopurin
  • 2-amino-6-purin-tiol
  • 2-aminopurin-6-tiol
  • 2-aminopurin-6(1H)-tion
  • 2-aminopurin-6-tiol-hemihidrát
  • 2-merkapto-6-aminopurin
  • 6-amino-2-merkaptopurin
  • 6-merkapto-2-aminopurin
  • 6-merkaptoguanin
  • 6H-purin-6-tion, 2-amino-1,7-dihidro-(9CI)
  • BW 5071
  • Lanvis
  • Bulvárlap
  • Tioguanin-hemihidrát
  • Tioguanin-hidrát
  • Tioguanin
  • Tioguanine
  • Üdv, U3B
  • WR-1141
  • X 27

Undergo HSCT

Más nevek:
  • Allogén
  • Allogén hematopoietikus sejttranszplantáció
  • Allogén őssejt transzplantáció
  • HSC
  • HSCT
  • Őssejt transzplantáció, allogén

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
Időkeret: Up to 3 years

Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone.

Up to 3 years

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
Időkeret: Up to 3 years

Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

Up to 3 years
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
Időkeret: Up to 2 years

The proportion of patients who receive at least 75% of intended doses.

Up to 2 years
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
Időkeret: Up to 3 years

Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events.

Up to 3 years
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
Időkeret: Up to 3 years

Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group.

Up to 3 years
EFS of all Ph+ patients
Időkeret: Up to 3 years

Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first.

Up to 3 years
Overall survival (OS) of all Ph+ patients
Időkeret: Up to 3 years

Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause.

Up to 3 years
OS of SR Ph+ patients
Időkeret: Up to 3 years

Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients

Up to 3 years
OS of SR Ph+ patients by randomization group
Időkeret: Up to 3 years

Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

Up to 3 years
OS of high risk Ph+ patients
Időkeret: Up to 3 years

Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients.

Up to 3 years
EFS of all eligibility ABL-class fusion positive ALL patients
Időkeret: Up to 3 years

Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients.

Up to 3 years
OS of all eligibility ABL-class fusion positive ALL patients
Időkeret: Up to 3 years

Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients.

Up to 3 years

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
Időkeret: Up to 2 years

Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection.

Up to 2 years
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
Időkeret: Up to 3 years

Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm.

Up to 3 years
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
Időkeret: Up to 6 months

For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB.

Up to 6 months
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
Időkeret: Up to 3 years

The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored.

Up to 3 years
MRD assessments made by IGH-TCR PCR assay and NGS assay
Időkeret: Up to 3 years

Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected.

Up to 3 years
IKZF1 deletions alone
Időkeret: Up to 3 years

Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

Up to 3 years
IKZF1 deletions with other transcription factor deletions
Időkeret: Up to 3 years

Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

Up to 3 years
Other identified genetic lesions
Időkeret: Up to 3 years

Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

Up to 3 years
Frequency of p190 and p210 BCR::ABL1 fusion variants
Időkeret: Up to 3 years

For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.

Up to 3 years
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
Időkeret: Up to 2 years

Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity.

Up to 2 years
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
Időkeret: Up to 2 years

Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity.

Up to 2 years
DFS of SR ABL-class fusion positive patients
Időkeret: Up to 3 years

Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

Up to 3 years
Secondary and exploratory aims applied to ABL-class fusion positive patients
Időkeret: Up to 3 years

Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.

Up to 3 years
Therapeutic impact of major secondary events
Időkeret: Up to 3 years

Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events.

Up to 3 years
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
Időkeret: Up to 3 years

Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients.

Up to 3 years
In vivo activity
Időkeret: Up to 3 years

Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.

Up to 3 years
Molecular heterogeneity
Időkeret: Up to 3 years

Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays.

Up to 3 years
Cellular heterogeneity
Időkeret: Up to 3 years

Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays.

Up to 3 years
CML-like phenotypes
Időkeret: Up to 3 years

Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.

Up to 3 years

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Együttműködők

Nyomozók

  • Kutatásvezető: Lewis B Silverman, Children's Oncology Group
  • Kutatásvezető: Andrea Biondi, EsPhALL Network/ BFM Study Group

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2017. augusztus 8.

Elsődleges befejezés (Tényleges)

2026. június 30.

A tanulmány befejezése (Becsült)

2034. szeptember 30.

Tanulmányi regisztráció dátumai

Először benyújtva

2016. december 28.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2016. december 28.

Első közzététel (Becsült)

2017. január 2.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. október 5.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. szeptember 30.

Utolsó ellenőrzés

2026. szeptember 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

További vonatkozó MeSH feltételek

Egyéb vizsgálati azonosító számok

  • AALL1631
  • U10CA180886 (Az Egyesült Államok NIH támogatása/szerződése)
  • 2017 (Az Egyesült Államok NIH támogatása/szerződése)
  • AALL1631 (Egyéb azonosító: CTEP)
  • NCI-2016-01588 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • 2017-000705-20
  • 2024-515499-12-00
  • AALL1631 (Egyéb azonosító: Children's Oncology Group)
  • 2017-000705-20 (EudraCT szám)
  • 2024-515499-12-00 (Ctis)

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .